Crizotinib

The FDA approved crizotinib for treatment of certain patients with systemic anaplastic large cell lymphoma.

Lorlatinib appeared to be an effective first-line therapy compared with crizotinib among patients with advanced ALK-positive non-small cell lung cancer, according to phase 3 study results published in The New England Journal of Medicine.

The FDA granted priority review to crizotinib for the treatment of certain children with lymphoma, according to the agent’s manufacturer.

Lorlatinib appeared superior to crizotinib as first-line treatment for advanced ALK-positive non-small cell lung cancer, according to an interim analysis of the randomized phase 3 CROWN study presented at ESMO Virtual Congress 2020.

Ensartinib significantly increased PFS compared with crizotinib for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer, according to an interim analysis of the phase 3, open-label eXalt3 study.

An estimated 800 new cases of neuroblastoma are diagnosed in the United States each year.

Brigatinib conferred a durable PFS benefit compared with crizotinib among patients with ALK-positive non-small cell lung cancer who had not received prior ALK inhibitor therapy, according to updated results of the phase 3 ALTA-1L trial presented at ESMO Asia.

In this video, Eunice Wang, MD, Chief of the Leukemia Service at Roswell Park Comprehensive Cancer Center, discusses new options that have entered the market for acute myeloid leukemia, including new targeted agents and therapies.